Home
Home
Information for Patients
Information for Patients
Information for Oncologists
Information for Oncologists
About Us
About Us
Contact Us
Contact Us
Links
Links
Principle of the Therapy
Autohaemocytokines are processed by us into a therapeutic substrate.
Cytokines are the natural information transmitter substances, the courier/messenger service of the immune system. In the past years, the importance of cytokines has increased greatly for clinical and for therapeutic purposes. Our therapy aims to alter part of the cells taken from the patient's own blood, in the laboratory in a specially developed procedure, in such a fashion that the treated blood, when returned to the patient, calls forth a defensive reaction which partly or completely destroys the tumor. It is a prerequisite that during the production process the processed cytokines show a successful accumulation in the cells, as they have a regulative effect on the immune system when it is returned to the patient.
In cancer, the maxim is always that the earlier the disease is recognized and treatment begun, the better are the chances of recovery. Frequently, however, when the cancer is not diagnosed early and or the patient has too little or no reaction to the traditional treatments, the disease progresses and produces metastasis. Especially in these cases, we recommend the administration of autohaemozytokines.
The results of general scientific studies (*) on treatments with autohaemo-products in comparison to treatments with foreign blood products show that the survival rate of patients who are treated with autohaemo-products is significantly higher than that of patients treated with foreign blood.
We wish however to explicitly point out that the therapy with autohaemocytokines is rated as an alternative therapy. Accordingly it is scientifically controversial, as are many cancer therapies—much as the value of chemotherapy is disputed in the great majority of tumor diseases. We cannot guarantee a complete recovery. The earnestness and seriousness of our procedure as well as the therapeutic effect has been confirmed in diverse medical certificates.
In addition, it is immensely important to maintain and to recover life quality of patients during the therapy. It is our goal, not only to conquer the cancer together with the patient, but also to maintain and better the patient's life quality. A scientific study to assess life quality during therapy with autohaemozyklines has shown a clear improvement of life quality in preliminary results.
Ensuring and protecting quality:
Our work in the production of autohaemocytokines is subject to constant quality control. We are accredited by the uppermost international laboratory authority, the COLLEGE OF AMERICAN PATHOLOGISTS. Very few laboratories in Germany have been awarded this certificate.
Excerpt from the textbook contribution
5.2.2 Technical Procedure
The physician in charge extracts blood from the patient with a medical instrument especially constructed/produced and provided for this purpose and sends it to the laboratory to be processed. In the lab, the erythrocytes are mechanically separated out and then also part of the remaining cell mixture, which now consists of mononuclear cells, According to cell density, that is about 25-30% of the number of cells. The next step is the attempt to deplete the outer parts of the cell membranes of these separated mononuclear cells, including their surface markers, for ex. CD44 v, through careful centrifugalizing. The individually differing consistence of the cell membranes of these mononuclear cells makes a very careful step by step procedure necessary. We begin at 800 rpm/10 min. Then we control it visually under the phase- contrast microscope. Important is the evaluation of the comparison of the cell membrane density of the untreated mononuclear cells to the treated mononuclear cells. For the induction of a relevant cytokine expression of the in-vitro incubation, at least 40-60% of the outer cell membrane parts must be depleted.
If the reduction of the cell membrane density has not been reduced enough, further centrifugation steps are required, whereby an increase of 300 rpm is advisable each time. The result is to be controlled by phase-contrast technique. A complete destruction of the cell membranes must however be avoided, because the resulting therapeutic substrate then would only work like a vaccine. In contrast, with laboratory-technical success, not only the exposed tumor cells, but also the tumor antigen-phagocytising macrophages can be presented in vitro. The previously separated untreated mononuclear cells (white blood cells) are then added in vitro and thus become antigen presentation modified mononuclear cells (tumor cells and macrophages). These and their separated cell surface parts are then presented in vitro to the untreated leucocytes via incubation. With this antigen presentation, we are able to spontaneously trigger antibody reactions, in particular without the addition of the classic immune activators, for example PHA, Freud's adjuvant or similar activators.
In contrast to other laboratory procedures, we use not only selectively determined cell populations, such as isolated natural killer cells or activated T-lymphocytes, but also the (mononuclear) immune competent cells of the peripheral blood as a whole. The aim and intention of the incubation process is to stimulate them to cytokine expression under development of their immunogenic powers and interactions in vitro all immune competent parts of the patient's blood to cytokine expression (spontaneous expression).
By not adding any allogenic or heterogeneous substances ( immune stimulators), we induce—initially in vitro—soley specific immune reactions and exclude thereby (in vitro) from the start unspecific immune reactions which target these heterogenic immune stimulators themselves. Thus, undesirable secondary reactions of unspecific genesis , such as are well known from conventional (unspecifically effective) immune stimulators, are avoided in clinical application (in vivo).With this in vitro technique, other immune active substances, for example the production of specific tumor antibodies, are apparently generated, aside from the cytokines. The cytokines are especially well suited as signal transducers for a sensitive proof of whether immunologic processes are indeed started during the incubation process. For this purpose, the following cytokines are determined before incubation (prae incubationem):
Tumor nekrose factor alpha (TNF-a)
Interferon 6 Rezeptor (IL 6-R) (**)
Interleukin 2 Rezeptor (s IL 2-R)
The measurements are undertaken with the Enzyme Linked Immuno Sorbent Assay (ELISA). After completion of the incubation and production process, the second measurement is made as described above, this time of the in vitro generated cytokines. The production and application as medication follows only when there is an enrichment of 200% or more of at least two of the three above mentioned cytokines. Otherwise, fresh blood must again be taken from the patient and the entire process repeated.
A voluntary additional quality proof, not required by law, is the accreditation by the College of American Pathologists (CAP) ensures that the quality controls also meet international standards.
(*) Heiss, Mempel et al.: Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeinic blood transfusion in colorectal cancer surgery. J. Clin. Oncol. 1994, Sept 12 (9); 1859-1865
(**) altered according to the current scientific research
The physician in charge extracts blood from the patient with a medical instrument especially constructed/produced and provided for this purpose and sends it to the laboratory to be processed. In the lab, the erythrocytes are mechanically separated out and then also part of the remaining cell mixture, which now consists of mononuclear cells, According to cell density, that is about 25-30% of the number of cells. The next step is the attempt to deplete the outer parts of the cell membranes of these separated mononuclear cells, including their surface markers, for ex. CD44 v, through careful centrifugalizing. The individually differing consistence of the cell membranes of these mononuclear cells makes a very careful step by step procedure necessary. We begin at 800 rpm/10 min. Then we control it visually under the phase- contrast microscope. Important is the evaluation of the comparison of the cell membrane density of the untreated mononuclear cells to the treated mononuclear cells. For the induction of a relevant cytokine expression of the in-vitro incubation, at least 40-60% of the outer cell membrane parts must be depleted.
If the reduction of the cell membrane density has not been reduced enough, further centrifugation steps are required, whereby an increase of 300 rpm is advisable each time. The result is to be controlled by phase-contrast technique. A complete destruction of the cell membranes must however be avoided, because the resulting therapeutic substrate then would only work like a vaccine. In contrast, with laboratory-technical success, not only the exposed tumor cells, but also the tumor antigen-phagocytising macrophages can be presented in vitro. The previously separated untreated mononuclear cells (white blood cells) are then added in vitro and thus become antigen presentation modified mononuclear cells (tumor cells and macrophages). These and their separated cell surface parts are then presented in vitro to the untreated leucocytes via incubation. With this antigen presentation, we are able to spontaneously trigger antibody reactions, in particular without the addition of the classic immune activators, for example PHA, Freud's adjuvant or similar activators.
In contrast to other laboratory procedures, we use not only selectively determined cell populations, such as isolated natural killer cells or activated T-lymphocytes, but also the (mononuclear) immune competent cells of the peripheral blood as a whole. The aim and intention of the incubation process is to stimulate them to cytokine expression under development of their immunogenic powers and interactions in vitro all immune competent parts of the patient's blood to cytokine expression (spontaneous expression).
By not adding any allogenic or heterogeneous substances ( immune stimulators), we induce—initially in vitro—soley specific immune reactions and exclude thereby (in vitro) from the start unspecific immune reactions which target these heterogenic immune stimulators themselves. Thus, undesirable secondary reactions of unspecific genesis , such as are well known from conventional (unspecifically effective) immune stimulators, are avoided in clinical application (in vivo).With this in vitro technique, other immune active substances, for example the production of specific tumor antibodies, are apparently generated, aside from the cytokines. The cytokines are especially well suited as signal transducers for a sensitive proof of whether immunologic processes are indeed started during the incubation process. For this purpose, the following cytokines are determined before incubation (prae incubationem):
Tumor nekrose factor alpha (TNF-a)
Interferon 6 Rezeptor (IL 6-R) (**)
Interleukin 2 Rezeptor (s IL 2-R)
The measurements are undertaken with the Enzyme Linked Immuno Sorbent Assay (ELISA). After completion of the incubation and production process, the second measurement is made as described above, this time of the in vitro generated cytokines. The production and application as medication follows only when there is an enrichment of 200% or more of at least two of the three above mentioned cytokines. Otherwise, fresh blood must again be taken from the patient and the entire process repeated.
A voluntary additional quality proof, not required by law, is the accreditation by the College of American Pathologists (CAP) ensures that the quality controls also meet international standards.
(*) Heiss, Mempel et al.: Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeinic blood transfusion in colorectal cancer surgery. J. Clin. Oncol. 1994, Sept 12 (9); 1859-1865
(**) altered according to the current scientific research
Principle of the Therapy
Principle of the Therapy
Illustrations
Illustrations
Video Footage
Video Footage
Press Release
Press Release
Patient's Assesments
Patient's Assesments
Publications
Publications
Press Release
Press Release
Lehrbuchbeitrag
Lehrbuchbeitrag
Principle of the Therapy
Principle of the Therapy
Laboratory Procedure
Laboratory Procedure
About Dr. Klehr
About Dr. Klehr
Munich
Munich
Salzburg
Salzburg
Laboratory Accreditations
Laboratory Accreditations